These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 23200176)

  • 1. A step towards treating KRAS-mutant NSCLC.
    Goldberg SB; Schlessinger J; Boyer JL; Herbst RS
    Lancet Oncol; 2013 Jan; 14(1):3-5. PubMed ID: 23200176
    [No Abstract]   [Full Text] [Related]  

  • 2. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study.
    Jänne PA; Shaw AT; Pereira JR; Jeannin G; Vansteenkiste J; Barrios C; Franke FA; Grinsted L; Zazulina V; Smith P; Smith I; Crinò L
    Lancet Oncol; 2013 Jan; 14(1):38-47. PubMed ID: 23200175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer.
    Jänne PA; Smith I; McWalter G; Mann H; Dougherty B; Walker J; Orr MC; Hodgson DR; Shaw AT; Pereira JR; Jeannin G; Vansteenkiste J; Barrios CH; Franke FA; Crinò L; Smith P
    Br J Cancer; 2015 Jul; 113(2):199-203. PubMed ID: 26125448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value.
    Mellema WW; Dingemans AM; Thunnissen E; Snijders PJ; Derks J; Heideman DA; Van Suylen R; Smit EF
    J Thorac Oncol; 2013 Sep; 8(9):1190-5. PubMed ID: 23787801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. AZD6244 inhibits cisplatin-induced ERK1/2 activation and potentiates cisplatin-associated cytotoxicity in K-ras G12D preclinical models.
    Kim EY; Kim A; Kim SK; Chang YS
    Cancer Lett; 2015 Mar; 358(1):85-91. PubMed ID: 25541062
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of KRAS-Mutant Non-Small Cell Lung Cancer: The End of the Beginning for Targeted Therapies.
    Kaufman J; Stinchcombe TE
    JAMA; 2017 May; 317(18):1835-1837. PubMed ID: 28492885
    [No Abstract]   [Full Text] [Related]  

  • 7. Are all KRAS mutations created equal?
    Stinchcombe TE; Der CJ
    Lancet Oncol; 2011 Aug; 12(8):717-8. PubMed ID: 21782508
    [No Abstract]   [Full Text] [Related]  

  • 8. KRAS mutations in non-small cell lung cancer.
    Riely GJ; Marks J; Pao W
    Proc Am Thorac Soc; 2009 Apr; 6(2):201-5. PubMed ID: 19349489
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. KRAS mutations in lung cancer.
    Karachaliou N; Mayo C; Costa C; Magrí I; Gimenez-Capitan A; Molina-Vila MA; Rosell R
    Clin Lung Cancer; 2013 May; 14(3):205-14. PubMed ID: 23122493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The clinical relevance of KRAS gene mutation in non-small-cell lung cancer.
    Tímár J
    Curr Opin Oncol; 2014 Mar; 26(2):138-44. PubMed ID: 24463346
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In situ evidence of KRAS amplification and association with increased p21 levels in non-small cell lung carcinoma.
    Wagner PL; Perner S; Rickman DS; LaFargue CJ; Kitabayashi N; Johnstone SF; Weir BA; Meyerson M; Altorki NK; Rubin MA
    Am J Clin Pathol; 2009 Oct; 132(4):500-5. PubMed ID: 19762526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of specific mutant KRAS on clinical outcome of EGFR-TKI-treated advanced non-small cell lung cancer patients with an EGFR wild type genotype.
    Metro G; Chiari R; Duranti S; Siggillino A; Fischer MJ; Giannarelli D; Ludovini V; Bennati C; Marcomigni L; Baldi A; Giansanti M; Minotti V; Crinò L
    Lung Cancer; 2012 Oct; 78(1):81-6. PubMed ID: 22770374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS mutations in non-small-cell lung cancer and colorectal cancer: implications for EGFR-targeted therapies.
    Maus MK; Grimminger PP; Mack PC; Astrow SH; Stephens C; Zeger G; Hsiang J; Brabender J; Friedrich M; Alakus H; Hölscher AH; Lara P; Danenberg KD; Lenz HJ; Gandara DR
    Lung Cancer; 2014 Feb; 83(2):163-7. PubMed ID: 24331409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low frequency KRAS mutations in colorectal cancer patients and the presence of multiple mutations in oncogenic drivers in non-small cell lung cancer patients.
    Jiang L; Huang J; Morehouse C; Zhu W; Korolevich S; Sui D; Ge X; Lehmann K; Liu Z; Kiefer C; Czapiga M; Su X; Brohawn P; Gu Y; Higgs BW; Yao Y
    Cancer Genet; 2013; 206(9-10):330-9. PubMed ID: 24200637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes by tumor histology and KRAS mutation status after lung stereotactic body radiation therapy for early-stage non-small-cell lung cancer.
    Mak RH; Hermann G; Lewis JH; Aerts HJ; Baldini EH; Chen AB; Colson YL; Hacker FH; Kozono D; Wee JO; Chen YH; Catalano PJ; Wong KK; Sher DJ
    Clin Lung Cancer; 2015 Jan; 16(1):24-32. PubMed ID: 25450872
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR and K-ras mutations in cytologic samples from fine-needle aspirates in NSCLC patients.
    Ulivi P; Zoli W; Chiadini E; Capelli L; Candoli P; Calistri D; Silvestrini R; Puccetti M
    Eur Respir J; 2012 Jul; 40(1):267-9. PubMed ID: 22753836
    [No Abstract]   [Full Text] [Related]  

  • 18. Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)?
    Macerelli M; Caramella C; Faivre L; Besse B; Planchard D; Polo V; Ngo Camus M; Celebic A; Koubi-Pick V; Lacroix L; Pignon JP; Soria JC
    Lung Cancer; 2014 Mar; 83(3):383-8. PubMed ID: 24439569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular alterations in non-small cell lung carcinomas of the young.
    VandenBussche CJ; Illei PB; Lin MT; Ettinger DS; Maleki Z
    Hum Pathol; 2014 Dec; 45(12):2379-87. PubMed ID: 25288236
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcome in resected non-small cell lung cancer patients.
    Ragusa M; Vannucci J; Ludovini V; Bianconi F; Treggiari S; Tofanetti FR; Flacco A; Colella R; Sidoni A; Crinò L; Puma F
    Am J Clin Oncol; 2014 Aug; 37(4):343-9. PubMed ID: 23357969
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.